Novo Nordisk disclosed negative top-line results from two large Phase 3 trials testing oral semaglutide in early symptomatic Alzheimer’s disease; investigators found no slowing of cognitive or functional decline versus placebo. The Evoke and Evoke+ programs enrolled approximately 3,800 patients with confirmed amyloid pathology. Novo said the trials did not show benefit on the Clinical Dementia Rating—Sum of Boxes endpoint. The failures deal a blow to efforts to repurpose GLP‑1 agonists for neurodegeneration and underscore the challenge of translating metabolic therapy hypotheses into disease-modifying Alzheimer’s outcomes.